Biotech Stock News (OREX) (TKPHF) (VRTX) (PBYI)

Orexigen Therapeutics (NASDAQ:OREX)  On May 12, 2015 Shares of Orexigen tanked by 13% after the company reported that the cardiovascular outcome study had to be terminated early. The “LIGHT” study recruited up to 9,000 patients to determine if patients taking Contrave have an increased risk of cardiovascular issues. The mess up occurred because the early … Read more

Biotech Stock News (OREX) (ABBV) (PCYC) (GILD) (OHRP)

Orexigen Therapeutics (OREX) Shares of Orexigen Therapeutics were up 40% on 3/3/15 when the company announced that early safety data showed that Contrave was not only safe to take but in addition it was able to reduce a patient’s risk of generating cardiovascular health issues such as a heart-attack. Contrave was approved by the FDA … Read more